相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naive patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial
Philip J. Mease et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Ixekizumab treatment of biologic-naive patients with active psoriatic arthritis: 3-year results from a phase III clinical trial (SPIRIT-P1)
Vinod Chandran et al.
RHEUMATOLOGY (2020)
Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials
Mark C. Genovese et al.
RHEUMATOLOGY (2020)
EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update
Laure Gossec et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naive to biological disease-modifying antirheumatic drug: final results by week 52
Josef S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Safety results of ixekizumab with 1822.2 patient-years of exposure: an integrated analysis of 3 clinical trials in adult patients with psoriatic arthritis
Bernard Combe et al.
ARTHRITIS RESEARCH & THERAPY (2020)
The contribution of joint and skin improvements to the health-related quality of life of patients with psoriatic arthritis: a post hoc analysis of two randomised controlled studies
Arthur Kavanaugh et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies
Dennis G. McGonagle et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Safety of Ixekizumab in Patients With Psoriatic Arthritis: Results From a Pooled Analysis of Three Clinical Trials
Philip Mease et al.
ARTHRITIS CARE & RESEARCH (2019)
Three Multicenter, Randomized, Double-Blind, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis
Atul Deodhar et al.
ARTHRITIS & RHEUMATOLOGY (2019)
Prevalence and outcome of latent tuberculosis in patients receiving ixekizumab: integrated safety analysis from 11 clinical trials of patients with plaque psoriasis
R. Romiti et al.
BRITISH JOURNAL OF DERMATOLOGY (2019)
Ixekizumab and complete resolution of enthesitis and dactylitis: integrated analysis of two phase 3 randomized trials in psoriatic arthritis
Dafna D. Gladman et al.
ARTHRITIS RESEARCH & THERAPY (2019)
Candida Infections in Clinical Trials of Ixekizumab (Taltz), an Interleukin-17A Monoclonal Antibody, in Patients With Psoriasis or Psoriatic Arthritis
Margaret Bobonich et al.
JOURNAL OF THE DERMATOLOGY NURSES ASSOCIATION (2019)
Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52-week Results from a Phase III Study (SPIRIT-P1)
Desiree van der Heijde et al.
JOURNAL OF RHEUMATOLOGY (2018)
Exposure-Response Modeling to Characterize the Relationship Between Ixekizumab Serum Drug Concentrations and Efficacy Responses at Week 12 in Patients With Moderate to Severe Plaque Psoriasis
Emmanuel Chigutsa et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2018)
Cutting Edge: Homeostasis of Innate Lymphoid Cells Is Imbalanced in Psoriatic Arthritis
Alina Soare et al.
JOURNAL OF IMMUNOLOGY (2018)
Ixekizumab treatment shows a neutral impact on cardiovascular parameters in patients with moderate-to-severe plaque psoriasis: Results from UNCOVER-1, UNCOVER-2, and UNCOVER-3
Alexander Egeberg et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)
Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-naive patients with active psoriatic arthritis (SPIRIT-P1)
Alice B. Gottlieb et al.
RHEUMATOLOGY (2018)
Safety and efficacy of ixekizumab in patients with PsA and previous inadequate response to TNF inhibitors: week 52 results from SPIRIT-P2
Mark C. Genovese et al.
RHEUMATOLOGY (2018)
Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial
Philip Mease et al.
LANCET (2018)
Preliminary development of a questionnaire assessing the impact of psoriasis and psoriatic arthritis on patient's perception of sexuality
Eric Esteve et al.
MEDICINE (2018)
Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor inhibitors
Peter Nash et al.
RMD OPEN (2018)
Achieving minimal disease activity in psoriatic arthritis predicts meaningful improvements in patients' health-related quality of life and productivity
Laura C. Coates et al.
BMC RHEUMATOLOGY (2018)
Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1
Philip J. Mease et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Secukinumab improves patient-reported outcomes in subjects with active psoriatic arthritis: results from a randomised phase III trial (FUTURE 1)
Vibeke Strand et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data
Bruce Strober et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial
Peter Nash et al.
LANCET (2017)
Enthesitis: from pathophysiology to treatment
Georg Schett et al.
NATURE REVIEWS RHEUMATOLOGY (2017)
Psoriatic Arthritis
Christopher T. Ritchlin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis
P. Mease et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Ixekizumab efficacy and safety with and without concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) in biologic DMARD (bDMARD)-naive patients with active psoriatic arthritis (PsA): results from SPIRIT-P1
Laura C. Coates et al.
RMD OPEN (2017)
Response to Tetanus and Pneumococcal Vaccination Following Administration of Ixekizumab in Healthy Participants
Elisa V. Gomez et al.
BIODRUGS (2017)
European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update
L. Gossec et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis
Laura C. Coates et al.
ARTHRITIS & RHEUMATOLOGY (2016)
Psoriatic Arthritis and Burden of Disease: Patient Perspectives from the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey
Arthur Kavanaugh et al.
RHEUMATOLOGY AND THERAPY (2016)
Evidence-based adverse effects of biologic agents in the treatment of moderate-to-severe psoriasis: Providing clarity to an opaque topic
Eric Sorenson et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2015)
Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial
Iain B. McInnes et al.
LANCET (2015)
Assessment of ixekizumab, an interleukin-17A monoclonal antibody, for potential effects on reproduction and development, including immune system function, in cynomolgus monkeys
D. O. Clarke et al.
REPRODUCTIVE TOXICOLOGY (2015)
Tumour necrosis factor α blockers are more effective than methotrexate in the inhibition of radiographic joint damage progression among patients with psoriatic arthritis
Lihi Eder et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial
Christopher Ritchlin et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study)
Arthur Kavanaugh et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor
Arthur Kavanaugh et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
IL-6 Regulates Neutrophil Microabscess Formation in IL-17A-Driven Psoriasiform Lesions
Andrew L. Croxford et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2014)
Depression and Anxiety in Psoriatic Disease: Prevalence and Associated Factors
Emily McDonough et al.
JOURNAL OF RHEUMATOLOGY (2014)
Psoriasis prevalence among adults in the United States
Tara D. Rachakonda et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2014)
Psoriasis beyond the skin: an expert group consensus on the management of psoriatic arthritis and common co-morbidities in patients with moderate-to-severe psoriasis
R. Strohal et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2014)
Interleukin-17+CD8+T Cells Are Enriched in the Joints of Patients With Psoriatic Arthritis and Correlate With Disease Activity and Joint Damage Progression
Bina Menon et al.
ARTHRITIS & RHEUMATOLOGY (2014)
Pathogenic role of IL-17 in psoriasis and psoriatic arthritis
A. Chiricozzi
ACTAS DERMO-SIFILIOGRAFICAS (2014)
The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing
Sarah L. Gaffen et al.
NATURE REVIEWS IMMUNOLOGY (2014)
EXTENDED REPORT Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review
Anna Jamnitski et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence
Rosa Parisi et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2013)
Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial
Iain B. McInnes et al.
LANCET (2013)
Interleukin-17-positive mast cells contribute to synovial inflammation in spondylarthritis
Troy Noordenbos et al.
ARTHRITIS AND RHEUMATISM (2012)
Psoriasis and risk of nonfatal cardiovascular disease in US women: a cohort study
W. -Q. Li et al.
BRITISH JOURNAL OF DERMATOLOGY (2012)
IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis
James G. Krueger et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2012)
Anti-IL-17 mAbs herald new options in psoriasis
Ken Garber
NATURE BIOTECHNOLOGY (2012)
Anti-Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis
Craig Leonardi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
A randomized placebo-controlled trial of methotrexate in psoriatic arthritis
Gabrielle H. Kingsley et al.
RHEUMATOLOGY (2012)
Anxiety and depressive symptoms and illness perceptions in psoriatic arthritis and associations with physical health-related quality of life
Konstantinos Kotsis et al.
ARTHRITIS CARE & RESEARCH (2012)
Cardiovascular and other comorbidities in patients with psoriatic arthritis: A comparison with patients with psoriasis
Janice A. Husted et al.
ARTHRITIS CARE & RESEARCH (2011)
Mechanisms of Disease: Interleukin-17 and Type 17 Helper T Cells.
Pierre Miossec et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Epidemiological and clinical characteristics of psoriatic arthritis in northern Norway
J. C. Nossent et al.
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY (2009)
Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides
Camilla Jandus et al.
ARTHRITIS AND RHEUMATISM (2008)
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
Craig L. Leonardi et al.
LANCET (2008)
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
Kim A. Papp et al.
LANCET (2008)
Insights into the pathology and treatment of spondyloarthritis: From the bench to the clinic
John C. Davis et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2008)
Adalimumab for long-term treatment of psoriatic arthritis - Forty-eight week data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial
Dafna D. Gladman et al.
ARTHRITIS AND RHEUMATISM (2007)
Prevalence of spondyloarthropathies in France: 2001
A Saraux et al.
ANNALS OF THE RHEUMATIC DISEASES (2005)
Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial
C Antoni et al.
ANNALS OF THE RHEUMATIC DISEASES (2005)
Etanercept treatment of psoriatic arthritis - Safety, efficacy, and effect on disease progression
PJ Mease et al.
ARTHRITIS AND RHEUMATISM (2004)
分享论文
